Users note Ace-031's appeal alongside TRT but flag poor side-effect profiles and early trial halts as reasons for caution. Limited real-world reports exist outside niche peptide discussions, with high costs and receptor specificity adding barriers. One user accidentally acquired some and is hesitant to use it. Receptor targeting differences between compounds like Ace-031, trevogrumab, FLGR242, and follistatin are compared but costs make practical testing unrealistic.
What this discussion establishesWhether any of these compounds can be made to work safely or affordably in practice
Nothing here is advice.
It looks fairly intriguing when stacked with TRT. Wondering whether anyone has actually tried it. The possible side effects do sound pretty rough though.
Given they stopped it after the second administration and ended the research, it might not be worth the downside.
There's a solid thread over on the peptide critic community about one person's experience with flgr242 and klotho. Other than that, it's so expensive and specialized that I haven't seen many reports from actual users.
Yeah, that's pretty much what I was thinking too. I threw it in by accident during a late-night order a while back. It's been sitting in the fridge staring at me ever since 😆
Something that stands out involves separate receptors tied to each activin variant. Getting the desired outcome seems impossible by hitting just one without also hitting the other. Certain compounds focus on the b variant while different ones act on the a variant. One additional substance leaves me uncertain about its precise role. Research on a b targeting compound used very large daily amounts. At prevailing rates that quickly adds up to an absurd daily total. I would give it a try right away except the monthly figure reaches into the millions. Lol
If you have tried it, this topic is still open. Sign in to reply — it takes a minute.